Table 1 Patient and tumor characteristics
From: A prospective feasibility study of a 1-mm bolus for postmastectomy radiotherapy
Patient and tumor characteristics | No. (%) |
|---|---|
Median age, years (range) | 59 (32–79) |
Median height, cm (range) | 155 (150–179) |
Median weight, kg (range) | 55 (43–74) |
Median BMI (range) | 21.8 (17.6–28.3) |
History of smoking | |
None | 14 (74) |
Former smoker | 5 (26) |
Diabetes | |
Yes | 1 (5) |
No | 18 (95) |
High blood pressure | |
Yes | 4 (21) |
No | 15 (79) |
Cardiovascular disease | |
Yes | 0 (0) |
No | 19 (100) |
Collagen disease | |
Yes | 0 (0) |
No | 19 (100) |
ECOG PS | |
0 | 18 (95) |
1 | 1 (5) |
Laterality | |
Left | 9 (47) |
Right | 10 (53) |
Clinical T stage | |
1b | 1 (5) |
1c | 3 (16) |
2 | 11 (58) |
3 | 3 (16) |
4b | 1 (5) |
Clinical N stage | |
0 | 2 (11) |
1 | 9 (47) |
2a | 3 (15) |
2b | 1 (5) |
3a | 2 (11) |
3b | 2 (11) |
Clinical stage group | |
IA | 1 (5) |
IIA | 4 (21) |
IIB | 6 (32) |
IIIA | 4 (21) |
IIIB | 1 (5) |
IIIC | 3 (16) |
Pathologic T stage | |
0 | 4 (21) |
1a | 2 (11) |
1c | 4 (21) |
2 | 6 (31) |
3 | 2 (11) |
4b | 1 (5) |
Pathologic N stage | |
0 | 3 (16) |
1mi | 2 (11) |
1a | 8 (42) |
2a | 5 (26) |
3a | 1 (5) |
Pathologic stage group | |
pCR | 2 (11) |
IA | 1 (5) |
IB | 2 (11) |
IIA | 2 (11) |
IIB | 4 (21) |
IIIA | 7 (36) |
IIIC | 1 (5) |
Receptor status | |
ER positive | 14 (74) |
ER negative | 5 (26) |
PR positive | 11 (58) |
PR negative | 8 (42) |
HER2 positive | 12 (64) |
HER2 negative | 7 (36) |
Surgical margin | |
Close | 4 (21) |
Negative | 15 (79) |
Chemotherapy delivery | |
Neoadjuvant | 10 (53) |
Adjuvant | 8 (42) |
No | 1 (5) |
Hormone therapy | |
Yes | 14 (74) |
No | 5 (26) |
Concurrent hormone therapy (yes) | 10 (53) |
Anti-HER2 therapy (trastuzumab + pertuzumab) | |
Yes | 8 (42) |
No | 11 (58) |
Concurrent Anti-HER2 therapy (yes) | 7 (36) |
Median chest wall separation, cm (range) | 19.0 (16.4–22.3) |